ACEA S.p.A. (ACE) Earnings Call Transcripts
ACEA S.p.A.'s Latest Earnings Call - May 21, 2026
In the Q2 2026 earnings call for Ascelia Pharma AB, management highlighted significant upcoming milestones, particularly the PDUFA date for their lead product, Orviglance, set for early July 2026. The company is targeting a substantial $800 million market opportunity in the U.S. for Orviglance, which addresses unmet medical needs in patients with severe renal impairment. Management confirmed that they are actively seeking commercialization partners to maximize the product's market entry and growth potential. Financial specifics regarding revenue and earnings were not disclosed during the call, and no guidance changes were mentioned.
Reported metrics
| Metric | Value |
|---|---|
| Market Opportunity | $800M (positive) |
| PDUFA Date | July 3, 2026 (positive) |
| Annual Procedures | 100,000 (positive) |
| Market Exclusivity | 7 years (positive) |
| Clinical Studies Completed | 9 (positive) |
Guidance from management
Management did not provide specific financial guidance or changes during the call, focusing instead on upcoming milestones related to Orviglance's approval and commercialization efforts.
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for Orviglance, particularly with GE Healthcare developing a similar manganese-based agent. There were also questions about the timeline and efficacy of securing a commercialization partner before the FDA decision.
Main topics on the call
- PDUFA Date for Orviglance — Ascelia Pharma is eagerly anticipating the FDA's decision on Orviglance, with the PDUFA date set for July 3, 2026. CEO Magnus Corfitzen expressed optimism, stating, "everything is pointing in the right direction" regardi...
- Market Opportunity — Orviglance targets an $800 million global market, with half of that in the U.S. The company has identified approximately 100,000 annual procedures in their target patient population, indicating a concentrated market for ...
- Commercialization Strategy — Management is focused on partnering with companies that have established sales forces in U.S. hospitals to drive Orviglance's market entry. Corfitzen noted, "we need a partner... who is really good at getting approved dr...
- Regulatory Process Insights — The management provided insights into the ongoing FDA review process, indicating a positive trajectory based on interactions with the agency. Corfitzen highlighted that they are "very happy with where we are now" in the ...
Read the full ACEA S.p.A. transcript (May 21, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ACEA S.p.A.
ACEA S.p.A. (ACE) is a publicly listed company in the Multi-Utilities industry, within the Utilities sector. It trades on BIT and is based in IT. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 90 calls on record spanning February 5, 2020 to July 24, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 90 ACEA S.p.A. earnings call transcripts on record, spanning February 5, 2020 to July 24, 2026. Based on this history, ACEA S.p.A. reports quarterly. The most recent call on file is dated July 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ACE
- Exchange
- BIT
- Country
- IT
- Sector
- Utilities
- Industry
- Multi-Utilities
- Calls on record
- 90
- First call
- February 5, 2020
- Most recent
- July 24, 2026
- Reporting cadence
- quarterly